Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous G-CSF-mobilized CD34+ cell transplantation for acute renal failure
jRCTb030190231Recruiting
- Start
- May 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of autologous CD34+ cells and filgrastim in acute kidney failure (AKF) (3 cohorts). Primary endpoint: Primary safety endpoint. Started May 2020; status: recruiting.
02
Drugs
autologous CD34+ cellsfilgrastim
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on jRCTb030190231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTb030190231.